palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + Fulvestrant
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER-2 Positive Breast Cancer
Conditions
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Trial Timeline
Jun 21, 2017 → Jul 31, 2026
NCT ID
NCT02947685About palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + Fulvestrant
palbociclib + trastuzumab + pertuzumab + letrozole + Anastrozole + Exemestane + Fulvestrant is a phase 3 stage product being developed by Pfizer for HER-2 Positive Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02947685. Target conditions include HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02947685 | Phase 3 | Active |
Competing Products
11 competing products in HER-2 Positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Trastuzumab + Capecitabine + Cisplatin | Celltrion | Phase 2 | 52 |
| eribulin + carboplatin + trastuzumab | Eisai | Phase 1/2 | 41 |
| Apatinib and S-1 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| V930 | Merck | Phase 1 | 33 |
| Everolimus + Vinorelbine + Trastuzumab | Novartis | Phase 2 | 52 |
| IV LBH589 + Oral LBH589 + trastuzumab + paclitaxel | Novartis | Phase 1 | 33 |
| T-DM1 | Roche | Phase 2 | 52 |
| Trastuzumab + Paclitaxel + Epirubicin + Carboplatin | Roche | Phase 2 | 52 |
| Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab | United Therapeutics | Phase 1/2 | 38 |
| Alisertib + Endocrine therapy | Puma Biotechnology | Phase 2 | 44 |
| Margetuximab + Trastuzumab + Physician's choice of chemotherapy. | MacroGenics | Phase 3 | 69 |